TENAGRITY SOLUTIONS, LLC lobbying for CENTER FOR ADDICTION SCIENCE, POLICY, AND RESEARCH

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Income

$20,000.00

What the client paid this registrant for the period.

Client based in

Rhode Island

Official filing document

Lobbyists on this filing 1

JENNY CAROLINE DEBERRY

Previously held: Senior Legislative Assistant/ Legislative Assistant, Congressman John J. Duncan, Jr.; Senior Campaign Finance Analyst/ Campaign Finance Analyst, Federal Election Commission

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 5

Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE
Veterans Affairs, Dept of (VA)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

S 2256
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
HR 4121
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026

Lobbying activity 4

Health Issues

Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD (including support letters and FY26 appropriations language: Ag-FDA S.2256, H.R. 4121); potential legislation to create a SUD PRV to increase development of and access to new SUD medicines. Support for the FDA Commissioners announced national PRV.

Veterans

Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access (for veterans and others) as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD (including support letters and FY26 appropriations language, Ag-FDA S.2256, H.R. 4121); potential legislation to create a SUD PRV to increase development of and access to new SUD medicines. Support for the FDA Commissioners announced national PRV.

Alcohol and Drug Abuse

Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD (including support letters and FY26 appropriations language, Ag-FDA S.2256, H.R. 4121); potential legislation to create a SUD PRV to increase development of and access to new SUD medicines. Support for the FDA Commissioners announced national PRV.

Budget/Appropriations

Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD (including support letters and FY26 appropriations language: Ag-FDA S.2256, H.R. 4121); potential legislation to create a SUD PRV to increase development of and access to new SUD medicines. Support for the FDA Commissioners announced national PRV.